Advice

in the absence of a submission from the holder of the marketing authorisation

tocilizumab (RoActemra®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.
 

Download detailed advice49KB (PDF)

Download

Medicine details

Medicine name:
tocilizumab (RoActemra®)
SMC ID:
1020/14
Indication:
Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
Pharmaceutical company
Roche
BNF chapter
Musculoskeletal and joint diseases
Submission type
Non submission
Status
Not recommended
Date advice published:
08 December 2014